Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TACR2 | P21452 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10264071 | 0.93 | CYP2C19 (0.69) | ALDH1A1SMN1; SMN2GAACYP2C9CYP2D6 | |
| SCHEMBL5476524 | 0.88 | SMYD2 (0.62) | ALDH1A1KDM4EGAAPARP1KMT2A | |
| SCHEMBL29818241 | 0.86 | TSHR (0.73) | ALDH1A1SMN1; SMN2KDM4EGAACYP2C9 | |
| SCHEMBL10192030 | 0.86 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2KDM4EGAACYP2C9 | |
| SCHEMBL8430041 | 0.85 | TSHR (0.73) | ALDH1A1SMN1; SMN2KDM4ECYP2C9CYP2D6 | |
| SCHEMBL22823029 | 0.83 | SMN1; SMN2 (0.70) | ALDH1A1SMN1; SMN2KDM4EGAACYP2C9 | |
| SCHEMBL12305542 | 0.83 | SMN1; SMN2 (0.65) | ALDH1A1SMN1; SMN2KDM4EGAACYP2C9 | |
| SCHEMBL1382764 | 0.82 | SMN1; SMN2 (0.95) | ALDH1A1SMN1; SMN2KDM4EGAACYP2C19 | |
| SCHEMBL13060850 | 0.82 | SMYD2 (0.67) | PARP1KMT2APOLB | |
| SCHEMBL12334148 | 0.82 | NPSR1 (0.58) | ALDH1A1CYP2C9CYP2D6CYP2C19PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | ALDH1A1 1869/4885SMN1; SMN2 2600/4885KDM4E 2939/4885 |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | ALDH1A1 820/4885SMN1; SMN2 2946/4885KDM4E 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.